by
Jason Fangusaro;
Pawel Buczkowicz;
Christine Hoeman;
Patricia Rakopoulos;
Sanja Pajovic;
Louis Letourneau;
Misko Dzamba;
Andrew Morrison;
Peter Lewis;
Eric Bouffet;
Ute Bartels;
Jennifer Zuccaro;
Sameer Agnihotri;
Mark Barszczyk;
Yevgen Chornenkyy;
Mathieu Bourgey;
Guillaume Bourque;
Alexandre Montpetit;
Francisco Cordero;
Pedro Castelo-Branco;
Joshua Mangere;
Uri Tabori
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.